Johnson B F, Wilson J, Marwaha R, Hoch K, Johnson J
Clin Pharmacol Ther. 1987 Jul;42(1):66-71. doi: 10.1038/clpt.1987.109.
Conflicting conclusions have been reported about interaction of calcium channel blockers with digoxin. The effects of verapamil (240 mg/day) and a new dihydropyridine calcium channel blocker, isradipine (15 mg/day), on the pharmacokinetics of 1 mg intravenous digoxin were compared. All 24 volunteer subjects were healthy, male, nonobese, and aged 18 to 38 years. Groups of 12 subjects received each oral agent over 15 days, with collections of blood and urine for 72 hours after intravenous digoxin. Significant (P less than 0.05) reduction in nonrenal (7.01 +/- 1.97 to 4.00 +/- 1.86 L/hr) and total clearance (14.1 +/- 2.6 to 11.5 +/- 2.5 L/hr) were induced by verapamil, without change in renal clearance. A near-significant (P less than 0.1) increase in peripheral volume of distribution contributed to prolonged elimination half-life (23.1 +/- 4.4 to 34.3 +/- 9.7 hours). By contrast, isradipine caused only a 9% reduction in volume of distribution. Verapamil causes digoxin accumulation by reducing nonrenal elimination. No evidence of clinically relevant interaction of isradipine with digoxin was seen.
关于钙通道阻滞剂与地高辛的相互作用,已有相互矛盾的结论报道。比较了维拉帕米(240毫克/天)和一种新型二氢吡啶类钙通道阻滞剂伊拉地平(15毫克/天)对1毫克静脉注射地高辛药代动力学的影响。所有24名志愿者均为健康男性,非肥胖,年龄在18至38岁之间。12名受试者为一组,在15天内服用每种口服药物,静脉注射地高辛后72小时采集血液和尿液。维拉帕米可使非肾清除率(从7.01±1.97升/小时降至4.00±1.86升/小时)和总清除率(从14.1±2.6升/小时降至11.5±2.5升/小时)显著降低(P<0.05),而肾清除率无变化。外周分布容积近乎显著增加(P<0.1),导致消除半衰期延长(从23.1±4.4小时延长至34.3±9.7小时)。相比之下,伊拉地平仅使分布容积减少9%。维拉帕米通过减少非肾清除导致地高辛蓄积。未发现伊拉地平与地高辛存在临床相关相互作用的证据。